This LucidWargames case study uses strategy wargaming to examine why FDA’s mixed Signal on Volixibat matters for Ipsen’s Rare-Liver Franchise and how the Ipsen–Mirum competition in PSC could evolve under different regulatory and stakeholder scenarios.
Download the 9-page PSC_Ipsen_Mirum_Wargame_Summary for the key scenarios, findings and strategic implications.
Breakthrough Therapy designation. A request for a Phase 3. In the same month.
In August 2026, FDA granted Mirum Pharmaceuticals’ volixibat Breakthrough Therapy and Orphan Drug designations for itch caused by primary sclerosing cholangitis (PSC). At its pre-NDA meeting, the agency also recommended a Phase 3 study. PSC has no approved therapy, and volixibat’s Phase 2b VISTAS study met its primary endpoint, with 56% of patients with moderate-to-severe itch achieving a meaningful reduction against 26% on placebo. The signal is strong. The path to approval is not settled.
For Ipsen, the stakes are different. Its rare-liver franchise includes Iqirvo in PBC and Bylvay in pediatric cholestasis, and its elafibranor PSC Phase 3, ELASCOPE, measures event-free survival over roughly five years. It will not read out before the end of the decade. Mirum could define what PSC treatment means before Ipsen has PSC data.
The question is not whether volixibat works. It is how regulators, payers, hepatologists and patient advocates will respond as the two companies compete to define the category, and what Ipsen can and cannot control.
We used strategy wargaming to simulate that.
What AI-Powered Strategy Wargaming Revealed About the PSC Category War
The AI-powered strategic simulation shows that Ipsen’s exposure in PSC is reputational, not regulatory. The regulatory path decides how far Mirum can go: across four futures, Mirum’s weighted score ranged from 50.6 to 63.5. Ipsen’s moved only 6.6 points.
The one measure Ipsen lost in every future was the trust of hepatologists and patients, and it lost that through its own team’s moves, not through anything the regulator decided.
What Is AI-Powered Wargaming?
LucidWargames uses AI-powered wargaming to stress-test strategy by simulating how competing teams and stakeholders respond as a scenario develops.
Learn more about how AI-powered wargaming works.
Why the Ipsen–Mirum Contest Is a Strong Strategy Wargaming Case
PSC is a category that has not yet been defined. The first approval will shape what clinicians, payers and patients expect from every therapy that follows.
The two companies are betting on different definitions:
Mirum: severe itch is an urgent, independently treatable problem, and fast symptom relief is the first priority.
Ipsen: durable leadership requires disease modification, safety and portfolio breadth.
Neither position is wrong. And the evidence for each matures on very different timelines.
There is a complication. Volixibat belongs to a drug class, IBAT inhibitors, that carries liver-monitoring and GI-tolerability warnings. Ipsen’s own Bylvay belongs to the same class.
This is exactly the type of scenario where stakeholder reactions, not just clinical data, determine the trajectory.
How the PSC Strategic Simulation Was Designed
Using LucidWargames, we modelled the competition for the PSC category from Q4 2026 to 2028.
The simulation included:
- four scenario variants, each a different regulatory and competitive future
- three iterative rounds per variant
- competing teams: Ipsen’s rare-liver portfolio team versus Mirum’s symptom-first challenger team, each played by AI personas
- an evidence base of 37 data points verified against public sources
Stakeholders modelled:
- regulators
- payers and HTA bodies
- hepatology key opinion leaders
- patient advocates
- adjacent competitors
The four futures ranged from Safety Reset, where FDA requires a completed Phase 3 and no filing is possible in the window, to Symptom-First Breakout, where volixibat is approved in early 2028. The other two were a contested middle path and a race in which Dr. Falk’s norucholic acid, a disease-directed PSC therapy with positive Phase 3 data, moves towards European approval.
Across all four futures, one outcome was consistent:
The simulated Ipsen team ended every variant with lower KOL and patient trust than it started with.
Why Ipsen’s Defence Breaks Under Stakeholder Pressure
The trust losses were not driven by the regulator. They were driven by how the Ipsen team chose to compete.
Its primary moves were constructive: burden-of-illness registries with patient groups, consensus panels on liver monitoring, and a framework that valued itch relief alongside disease modification. But when Mirum moved, the simulated Ipsen team responded by attacking volixibat’s liver and GI safety, in nearly every round of every variant. Hepatologists and advocates penalised it each time, because the same warnings apply to Ipsen’s own Bylvay.
The result is structural: When a rival’s weakness is also your own, attacking it costs you more than it costs them.
Six Strategic Findings From the PSC Wargame
The Asymmetric Exposure
The regulatory path moved Mirum’s weighted score by 12.9 points across the four futures, and its regulatory position alone by 23. Ipsen’s moved 6.6. Ipsen cannot control volixibat’s approval, and gains little from trying.
The Mirror Problem
Bylvay is an IBAT inhibitor too. Attacking the class’s safety profile cost Ipsen trust in every variant, and trust recovered only in the rounds where the attacks stopped.
The Bundle Advantage
In the final round of three variants, including the one where volixibat was approved, payers chose Ipsen’s multi-product portfolio contracting. Ipsen’s access position was the strongest of either team in every future.
The Two-Key Rule
Payers kept an off-label step edit in every variant, and every variant also accepted evidence on sleep and daily function. Access needed both keys, never one. Neither blanket access nor blanket restriction survived.
The Full-Spectrum Settlement
Hepatologists backed a model that pairs symptom relief with disease modification in 8 of 12 rounds. They rejected claims that itch relief itself modifies disease, and also refused to treat itch as secondary.
No Deal Inside the Window
Left to decide for itself, the Ipsen team chose different external-innovation strategies in each future, from declining Phase 3 licensing to pursuing US rights to norucholic acid. None changed its portfolio score before 2028. Conduct and contracting did more than any transaction.
How Key Stakeholders Shape the PSC Category
Regulators act on the evidence they have, and the path they choose sets the ceiling for a symptom-first launch. Breakthrough designation creates access to the agency, not a guaranteed filing basis.
Payers neither reward nor block symptom relief outright. They demand a documented generic failure and functional evidence, and they reward sponsors who share risk.
Key opinion leaders refuse the choice between symptom relief and disease modification. Any strategy that forces that choice loses them.
Patient advocates hold an effective veto over how a company is perceived. They penalise any sponsor that appears to downplay severe itch, and they equally refuse to have safety concerns dismissed.
Adjacent competitors reset the benchmark. Norucholic acid’s histology data and linerixibat’s approval in PBC itch shape expectations for both Ipsen and Mirum.
Three Strategic Questions That Will Determine Ipsen’s Position in PSC
The value of Ipsen’s PSC strategy depends on resolving three questions before 2028:
How can Ipsen raise legitimate monitoring standards without being seen to attack a drug class it also sells?
How much monitoring burden does it take to cancel out the value of itch relief for payers?
Which interim markers could carry Ipsen’s disease-modification story before ELASCOPE reads out?
These are not downstream considerations. They decide whether Ipsen shapes the category or reacts to it.
Why Strategy Wargaming Reveals What Traditional Analysis Misses
Conventional approaches rely on historical benchmarks and linear projections.
They miss:
- how a team’s own competitive instincts can work against it
- how stakeholders read an attack on a shared drug class
- how payers combine restriction and reward rather than choosing one
AI-powered wargaming surfaces these dynamics before they materialise.
In this case, the strategic simulation showed that Ipsen’s greatest PSC risk is not a regulatory decision it cannot control. It is a reputational cost it can avoid.
What This Means for PSC Strategy
FDA’s August decision leaves volixibat’s path open. The science is credible on both sides. Mirum’s speed and Ipsen’s breadth are both real advantages. The constraint is how each company behaves while the category is being defined, and how regulators, payers, hepatologists and patients read that behaviour.
AI-powered strategy wargaming does not predict outcomes. It exposes the forces that shape them.
Before the filing. Before the first launch. Before positions are locked in.
That is where its value sits.
Note: The scenario variants describe hypothetical futures, not reported events, and team behaviour reflects AI personas modelled on each company’s strategic position, not the actions of Ipsen or Mirum. The wargame was grounded on publicly available data.
Download the full AI-Powered PSC_Ipsen_Mirum_Wargame_Report by LucidWargames to explore the complete simulation. This is how LucidWargames stress-tests strategy before it plays out in the real world.
What Strategic Assumption Is Your Team Making?
AI-powered wargaming helps teams test ..
Explore more AI-powered wargaming scenarios to see how regulators, payers, competitors, KOLs, and other stakeholders reshape outcomes across biopharma markets.
Facing a high-stakes strategic decision?
LucidWargames can build a custom AI-powered wargame around your product, market, or competitive challenge.
Contact us at info@lqventures.com.